Casali A, Verri C, Paoletti G, Tropea F, Modugno G, Frasca A M, Ameglio F, Tonachella R, Gallo Curcio C
Department of Medical Oncology II, Regina Elena Institute for Cancer Research, Rome, Italy.
Chemioterapia. 1988 Oct;7(5):327-9.
Sixty-five cancer patients pretreated with chemo or radiotherapy, with granulocytopenia less than 1000/mm3 and without fever, were entered into this study: 30 of them were submitted to prophylaxis with norfloxacin while the remaining 35 patients were used as a control group. 20% of the treated subjects versus 68.6% of the controls presented a subsequent infection (P less than 0.001), the lung representing the most frequent site of the infectious disease in both groups (3/6 and 14/24 respectively). These data strongly suggest the use of norfloxacin as an effective prophylactic drug in nonfebrile, granulocytopenic cancer patients, especially as far as gram-negative infections are concerned. Because of the high prevalence of lung cancer in the patients of our study, and a related prevalence of lung infections, at the present time, a wider use of this antibiotic in every kind of solid tumor cannot be generalized.
65例曾接受化疗或放疗的癌症患者，粒细胞减少症患者，粒细胞计数低于1000/mm3且无发热症状，纳入本研究：其中30例接受诺氟沙星预防治疗，其余35例患者作为对照组。治疗组患者继发感染率为20%，而对照组为68.6%（P<0.001），肺部是两组中最常见的感染部位（分别为3/6和14/24）。这些数据有力地表明，诺氟沙星可作为非发热性粒细胞减少症癌症患者的有效预防药物，尤其是对于革兰氏阴性菌感染。由于本研究患者中肺癌患病率较高，以及肺部感染相关患病率较高，目前，这种抗生素在各类实体瘤中的广泛应用尚不能一概而论。
